secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K/A
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001356576-25-000062
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus closes Sage acquisition for $8.50/share + CVRs; pro forma shows $118M H1 loss
--------------------------------------------------------------------------------

- Acquisition closed July 31, 2025; Supernus paid $8.50 per share cash plus CVRs up to $3.50 per share.
- Pro forma net loss of $118.2M for six months ended June 30, 2025; $415.9M loss for FY 2024.
- Contingent consideration liability of $35.7M recorded for CVRs tied to ZURZUVAE sales milestones.
- Sage's marketed drug ZURZUVAE (postpartum depression) added to Supernus portfolio; collaboration with Biogen.
- Supernus funded acquisition with cash and marketable securities; equity awards settled in cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000062/0001356576-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000062/supn-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer